We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Guidelines for Antitrypsin Deficiency

By HospiMedica staff writers
Posted on 22 Oct 2003
New guidelines for the diagnosis and management of patients with alpha-1 antitrypsin (AAT) deficiency have been issued by an international group comprising the American Thoracic Society, the European Respiratory Society, and the Alpha-1 Foundation. More...
The guidelines were published in the October 1, 2003, issue of the American Journal of Respiratory and Critical Care Medicine.

AAT is a hereditary disorder that can cause liver and lung disease, but it is frequently under-recognized and misdiagnosed by doctors, according to the new report entitled "Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency.” Under the new guidelines, doctors are urged to look for certain features that should raise their index of suspicion about the presence of this problem. These features include early onset of emphysema (age 45 or less); emphysema without the presence of other recognized risk factors such as smoking and occupational dust exposure; and a family history of emphysema, together with several other lung diseases. From a clinical standpoint, pulmonary emphysema appears to be related most prominently to the deficiency and is a major cause of disability and death.

For related liver disease, relatives with liver disease have a significant risk. Cirrhosis and carcinoma of the liver affect about 30-40% of those with AAT deficiency over the age of 50. The obstructive lung disease associated with the deficiency is treatable with general medical management. However, no specific therapy for advanced liver disease is available other than transplantation.




Related Links:
American Thoracic Society
European Respiratory Society
Alpha-1 Foundation

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.